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Preface
Since early 2020, the COVID-19 pandemic has had a dramatic impact on the way we 
live, as countries in Europe and around the world have had to introduce unprecedented 
measures to protect public health. All aspects of the phenomenon in Europe, including the 
production, trafficking, distribution and use of drugs, have also been affected by this crisis. 
The European Drug Report (EDR) 2021: Trends and Developments provides an overview of 
these developments and, supported by the Statistical Bulletin, presents the latest data and 
statistics from our national partners. This report offers you a top-level overview in a concise 
graphic-rich format, with links to a wealth of online information provided by the EMCDDA. 
This year’s EDR identifies the continued and escalating challenges to both public health 
and our security created by the trafficking of drugs into Europe and the production of illicit 
drugs within our borders. The resilience of organised crime groups involved in the drug 
trade is highlighted by the preliminary finding that the availability of drugs in Europe has not 
been seriously affected by the current pandemic. Rather, we continue to observe the risks 
to public health arising from the availability and use of a wide range of substances, often 
of high potency or purity. As Europe’s drug problems continue to rapidly evolve, so too must 
Europe’s response to drugs. The analysis of the impact of COVID-19 also reveals that while 
some services for those with drug problems have been disrupted, the care sector has also 
adapted rather quickly, and services were able to introduce innovative working practices to 
mitigate the impact of the current crisis on their clients. At the policy level, the new EU drugs 
strategy and action plan (2021-25), while reaffirming the European Union’s commitment on 
a balanced and evidence-based approach to the drugs phenomenon, provide a robust and 
comprehensive framework for concerted action to protect and improve public health and 
wellbeing and to offer a high level of security. I am pleased to note the explicit recognition 
given by the new strategy to the important role the EMCDDA and its partners play in 
producing the evidence needed for effective policies and actions in this area. 
In conclusion, at this challenging time, I wish to give special thanks to the colleagues in the 
Reitox network of national focal points, our other national and international partners and the 
Scientific Committee of the EMCDDA, whose support has been essential for this report. I also 
gratefully acknowledge the contribution of the many European research groups and experts, 
who have helped enrich the analysis presented here, and the crucial input we have received 
from our European partners: the European Commission, Europol, the European Medicines 
Agency and the European Centre for Disease Prevention and Control. 
Laura d’Arrigo 
Chair, EMCDDA Management Board
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Introductory note
This report is based on information provided to the EMCDDA by the EU Member States, 
Turkey and Norway, in an annual reporting process.
The purpose of the current report is to provide an overview and summary of the European 
drug situation up to the end of 2020. All grouping, aggregates and labels therefore reflect the 
situation based on the available data in 2020 in respect to the composition of the European 
Union and the countries participating in EMCDDA reporting exercises. The United Kingdom 
left the European Union as of 1 February 2020 and is not included in the analysis presented 
in this report. UK data for 2019 can be found in the country data tables annex. Due to the time 
needed to compile and submit data, many of the annual national data sets included here 
are from the reference year January to December 2019. Data, where it is available reflecting 
the composition of the EU up to 2019 can be found in our Statistical Bulletin. Analysis of 
trends is based only on those countries providing sufficient data to describe changes over the 
period specified and reflects wherever possible the countries participating in the European 
information system in 2020 (the EU Member States, Turkey and Norway). Some data from 
other countries may also be included for contextual reasons or because we are reporting on 
data collection exercises with a broader membership. The reader should also be aware that 
monitoring patterns and trends in a hidden and stigmatised behaviour such as drug use is 
both practically and methodologically challenging. For this reason, multiple sources of data 
are used for the purposes of analysis in this report. Although considerable improvements 
can be noted, both nationally and in respect to what is possible to achieve in a European 
level analysis, the methodological difficulties in this area must be acknowledged. Caution 
is therefore required in interpretation, in particular when countries are compared on any 
single measure. The number of countries with available data varies per indicator, and along 
with differences in reporting practices and national systems, this makes direct comparisons 
between countries difficult. The analysis offered here must be regarded as preliminary as a 
result of the impact of COVID-19 and requires confirmation as more information becomes 
available. Caveats relating to the data are to be found in the online Statistical Bulletin, which 
contains detailed information on methodology, qualifications on analysis and comments 
on the limitations in the information set available. Information is also available there on the 
methods and data used for European level estimates, where interpolation may be used. 
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are the national authorities providing drug information to the EMCDDA. The contact 




What are the lessons to be learnt from the EDR 2021? 
The new EU drugs strategy 2021-25 makes explicit that the European response to drugs 
should be evidence-based and delivered through a balanced and integrated approach, which 
ultimately must be judged on its impact on the health, safety and wellbeing of our citizens. 
The EMCDDA is tasked with helping to provide the evidence needed to ensure that European 
policies and actions on drugs are effective, well-targeted and responsive to new threats and 
challenges. The European Drug Report (EDR) 2021 arrives at a difficult time for meeting this 
objective, as the COVID-19 pandemic has impacted greatly on all areas of life, including the 
drug situation and our ability to monitor it. I am therefore extremely pleased that we can still 
provide the detailed analysis presented in this report, which includes an early assessment of 
the effect of the pandemic on drug markets and drug use. However, I also believe the value of 
our work is not simply delivered through accurately documenting past events. We also need 
to look forward and consider what lessons emerge from the findings of the EDR 2021 in 
order to ensure that we continue in the future to provide the relevant and timely information 
required to keep our policies and actions commensurate with the growing challenges we 
face in the drugs area.
In 2019, the EMCDDA conducted, with its stakeholders, a foresight and horizon-scanning 
exercise to increase our awareness of how the evolution of the drug situation may impact on 
our work. Among the overarching conclusions of this work was that many of the factors that 
would shape the drug problems of the future were external ones. Globalisation, developments 
in information technology, demographic shifts, alongside issues like climate change and 
human migration, are likely to have important implications for the future drug problems we 
face. We already see this, as both the drug market and patterns of drug use are becoming ever 
more dynamic, complex and globally connected. This has made us reflect on the need for more 
timely reporting, and to consider if both the data sources we use and the targets we select for 
our analysis are sufficient to meet both current and future policy development needs. 
What we did not expect was that the events of 2020 would demonstrate so profoundly 
the importance of this reflection. Within a few weeks, we needed to reorientate our work 
to support our stakeholders by providing enhanced resources for sharing information and 
best practices. The speed of developments required us to recognise that this could only be 
achieved through a more interactive model for knowledge co-production. I am proud of the 
work of the EMCDDA during this period, but I recognise that this was only possible because 
of the input we received from stakeholders across Europe. Particularly important was the 
possibility provided by our Reitox network of national focal points to engage in an ongoing 
conversation on national responses to the pandemic. This highlighted the value of sharing 
experiences and preliminary information when there is a need for rapid action. Beyond 
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this, we also launched a series of trendspotter studies to collate qualitative and emerging 
quantitative data to provide a near real-time complementary data source to accompany our 
routine monitoring information. The latest insights from our third COVID-19 trendspotter, 
published recently, are summarised here. These results are preliminary, but they help us 
identify some of the possible longer-term effects of the pandemic on drug markets, drug use 
and our responses. 
Despite interdiction efforts, all our routine indicators suggest that at the beginning of 2020 the 
European drug market was characterised by the widespread availability of a diverse range of 
drugs of increasingly high purity or potency. This is illustrated by the large seizures of cocaine 
and other drugs we observed during 2020. We can also see from a range of indicators that 
patterns of use are becoming more complex, with people who use drugs being presented 
with a greater selection of substances. This is creating various health harms, as a result of the 
use of more novel substances or from the interaction of the effects when multiple substances 
are used in combination. This convinces me that we need to invest more in understanding 
the implications of patterns of polydrug use and how they can increase harm. An example of 
this is visible in the growing concerns around the misuse of benzodiazepines diverted from 
therapeutic use or appearing as new benzodiazepines on the new psychoactive substances 
market. These substances can be harmful in themselves but when combined with opioids 
or alcohol they also increase the risk of overdose, though their role may go undetected. This 
kind of polydrug use, and more generally the growing importance of synthetic substances, 
highlights the urgent need to further develop forensic and toxicological resources if we are to 
better understand and respond to the increasingly complex drug problems we face today.
As you will see from the data presented here, cannabis is another area in which the issues 
we face are growing in complexity, which is only likely to increase in the future. We are seeing, 
partly because of developments outside of the European Union, more forms of cannabis 
appearing and new ways of consuming them emerging. Within Europe, we also see concerns 
growing about the availability of high-potency products on the one hand, and how to respond 
to low-THC products on the other hand. Synthetic cannabinoids, and the health risks they 
pose, only complicate this picture further, as evidenced by deaths reported in 2020 linked to 
the use of these substances and the fact that we have recently had to release public health 
alerts warning of the presence on the market of natural cannabis products adulterated with 
highly potent synthetic cannabinoids. I believe that providing policymakers with the up-to-
date and scientifically robust information they need in this area will be of growing importance 
for the work of the EMCDDA over the coming years. 
Drug production and trafficking appears to have adapted rapidly to pandemic-related 
restrictions, and we have seen little evidence of any major disruptions in supply. Social 
distancing measures may have affected retail drug dealing, but this appears to have led to 
a greater adoption of new technologies to facilitate drug distribution, possibly accelerating 
the trend we have seen in recent years, where the market is becoming increasingly digitally 
enabled. More positively, technology has also created opportunities for responding to 
drug problems. We can see this in the way that many drug services in Europe have also 
demonstrated resilience by adopting telemedicine approaches to allow them to continue 
offering support to people who use drugs during this difficult period. 
The EMCDDA is also increasingly incorporating innovative approaches to monitoring and 
developing new data sources that complement established indicators. This is essential, in 
my view, if we are to keep pace with the changes we are seeing and meet our stakeholders’ 
needs by reporting on the role drugs play in exacerbating problems across a broader set 
of policy areas. Digitalisation also offers us greater opportunities, I believe, in the future for 
working more dynamically and interactively with our stakeholders to ensure that our policies 
9
Director’s message
and actions in the drugs area are informed by a sound understanding of contemporary drug 
problems and shaped by a shared understanding of the most effective responses.
In conclusion, the data provided by the EDR 2021 illustrate how much the drug situation has 
changed over the last 25 years. The events of the past year also highlight a growing need 
to respond rapidly, and this requires us to increase our capacity for the early identification 
of threats emerging from an increasingly dynamic and adaptive drug market. Today, drugs 
have become a much more pervasive problem, one that impacts in some way across all 
major policy areas. We also see diversification, both in the products available and the people 
who use them. To ensure we are well-prepared to meet the future consequences of this 
hyper-availability, we need urgently to recognise that not only is a wider variety of people now 
personally experiencing drug problems, but drug problems are impacting on our communities 
in a wider variety of ways. This is why I believe it is crucial, across the areas of social, health 
and security policy, to develop the evidence-based and integrated responses envisioned by 
the new EU drugs strategy.
Alexis Goosdeel
EMCDDA Director
 We need urgently to recognise 
 that not only is a wider variety 
 of people now personally  
 experiencing drug problems,  
 but drug problems are  
 impacting on our communities 
 in a wider variety of ways  
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The routine data that underpin this report mostly refer to 
the period up to the end of 2019. To respond to information 
needs during the ongoing public health emergency and 
gain insight into it, the EMCDDA has worked with other EU 
agencies and national data providers to create resources 
for the rapid identification and sharing of information 
relevant to our stakeholder groups. An online gateway to 
these can be found on our website. The EMCDDA has 
also conducted a series of rapid ‘trendspotter’ studies, 
which triangulate data from key informants, national focal 
points, online surveys of people who use drugs, city-based 
wastewater analysis, and emerging data from established 
and developmental indicators and research studies. While 
the lack of comprehensive data means that all conclusions 
must be made with caution and be regarded as preliminary, 
it is useful to reflect on our current understanding of 
developments in this area. The results from the most recent 
of these studies can be found in detail in our accompanying 
trendspotter report. One of the main conclusions of our 
work is that the drug market has been remarkably resilient 
to disruption caused by the pandemic. Drug traffickers 
have adapted to travel restrictions and border closures. 
At wholesale level this is reflected in some changes in 
routes and methods, with more reliance on smuggling via 
intermodal containers and commercial supply chains and 
less reliance on the use of human couriers. Although street-
based retail drug markets were disrupted during the initial 
lockdowns, and some localised shortages were experienced, 
drug sellers and buyers appear to have adapted by 
increasing their use of encrypted messaging services, social 
media applications, online sources and mail and home 
delivery services. This raises the concern that a possible 
long-term impact of the pandemic will be to further digitally 
enable drug markets. 
The information at hand suggests that any reductions in 
drug consumption seen during the initial lockdowns rapidly 
disappeared as social distancing measures were eased. In 
general terms, there appears to have been less consumer 
interest in drugs usually associated with recreational events, 
such as MDMA, and greater interest in drugs linked with 
home use. However, the easing of restrictions on movement 
and travel and a return of some social gatherings during the 
summer was associated with a rebound in the levels of use. 
Analysis of wastewater samples, while only available from 
some cities, is informative here. The available data suggest 
that levels of use of most drugs appear generally lower 
during the initial lockdowns, but then appear to bounce back 
once lockdown was lifted. A comparison with 2019 appears 
to suggest similar overall consumption of most drugs, and 
in several cities possibly even higher levels, based on this 
data source.  Exceptions here appear to be MDMA and 
methamphetamine, two drugs for which the levels observed 
in 2020 appear lower in most of the participating cities. 
Less consumer interest in MDMA during 2020 is supported 
by user reports from online surveys, where a decline in use 
was noted, and some limited data on hospital emergencies, 
which showed a decline in MDMA-related presentations. This 
is against a background of high availability of this drug, as 
indicated by the continued detection of high-strength tablets 
in most countries. Interestingly, Dutch drug monitoring 
services reported the introduction of lower-strength tablets, 
apparently marketed as more suitable for home use.  
Online survey data from people who self-report drug use 
also suggest higher consumption of alcohol and greater 
experimentation with psychedelics, such as LSD and 2-CB 
(2,5-dimethoxy-4-bromophenethylamine), and dissociative 
drugs such as ketamine. This may reflect a growth in 
demand for substances possibly perceived as more 
suitable for home consumption. Survey data also suggest 
that those using drugs occasionally prior to COVID-19 
may have reduced or even ceased their use during the 
pandemic, but more-regular users may have increased their 
drug consumption. While these findings are preliminary 
and require research follow-up, they could have important 
implications if the changes observed are substantiated and 
persist into the future. 
COVID-19 PANDEMIC AND 
THE DRUG SITUATION
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COVID-19 pandemic and the drug situation
Among the possible worrying developments associated with 
the pandemic is the observation that some countries may be 
seeing an increase in crack cocaine availability and use. Also 
of concern are reports of the availability of smaller doses or 
cheaper packages of heroin, crack and benzodiazepines. 
Drug problems are often found in marginalised groups such 
as the homeless, and those with drug problems may often 
rely on the informal economy. It is likely that these groups 
have been financially disadvantaged by social distancing 
measures and may be particularly vulnerable to any future 
economic difficulties resulting from the current crisis. 
Growing concerns were also noted about the misuse of 
benzodiazepines, either diverted from therapeutic use or 
benzodiazepines not licenced for medical use in Europe 
appearing on the illicit drug market. Increased use of 
benzodiazepines was seen among high-risk drug users, 
prisoners and some groups of recreational drug users, 
potentially reflecting the high availability and low cost of 
these substances and pandemic-related mental health 
issues. A sample of sentinel hospitals observed an increase 
in emergency presentations related to benzodiazepines 
in 2020 compared with 2019. To accompany this report, 
the EMCDDA is releasing a study on new benzodiazepines 
available in Europe. This class of drugs merits closer 
attention as their use in combination with other psychoactive 
substances, including opioids and alcohol, increases the risk 
of fatal and non-fatal overdoses and can be associated with 
violent or aberrant behaviours. 
Reports indicate that cannabis cultivation and synthetic 
drug production within the European Union continued at 
pre-pandemic levels during 2020. Diversification of drug 
trafficking routes was observed, with more cannabis and 
heroin smuggled by sea, to avoid land border closures, 
leading to large seizures in Europe’s ports. Some changes 
were observed in the departure locations of cocaine 
trafficked from Latin America to Europe. However, no decline 
in supply was evident, and multi-tonne seizures of cocaine 
were reported in European ports in 2020 and early 2021, 
including 16 tonnes in Hamburg in Germany and 7.2 tonnes 
in Antwerp in Belgium. A trend towards home cultivation 
of cannabis, partially driven by lockdown measures, 
appears to have continued in 2020. An increase in reports 
of cannabis adulterated with synthetic cannabinoids has 
raised concerns. It is not known what could be driving this 
development but it could possibly reflect both shortages 
of cannabis linked to the pandemic or, possibly in some 
countries, criminal groups exploiting the availability of low-
THC cannabis products, which may be difficult to distinguish 
from cannabis sold on the drug market. Any scenario where 
people unwittingly consume synthetic cannabinoids is 
worrying given the toxicity of some of these substances, as 
illustrated by an outbreak of over 20 deaths related to the 
synthetic cannabinoid 4F-MDMB-BICA in 2020. 
Drug services across Europe had resumed their operations by 
June 2020, although at reduced capacity due to COVID-19 
prevention measures. In six countries that reported monthly 
data for 2020, the numbers entering treatment fell sharply 
between February and March, and remained at low levels 
for the rest of the year. A greater use of telemedicine may 
have contributed to the reduction in reported treatment 
demand but also allowed services to continue to meet their 
clients’ needs during the pandemic. Treatment services in 
prison settings also report service disruptions due to social 
distancing and restrictions on external service providers. 
Restrictions on access by external visitors and contractors 
to prisons also are also reported to have temporarily reduced 
the availability of drugs in some prisons. 
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LATEST DATA
 Around 83 million or 28.9 % of adults (aged 15-
64) in the European Union are estimated to have
used illicit drugs at least once in their lifetime. This
should be regarded as a minimum estimate due to
reporting biases.
 Experience of drug use is more frequently reported by 
males (50.6 million) than females (32.8 million). 
 The most commonly tried drug is cannabis  
(47.6 million males and 30.9 million females).
 Much lower estimates are reported for the lifetime 
use of cocaine (9.6 million males and 4.3 million 
females), MDMA (6.8 million males and 3.5 million 
females) and amphetamines (5.9 million males and 
2.7 million females).
 Levels of lifetime use of cannabis differ considerably 
between countries, ranging from around 4 % of adults 
in Malta to 45 % in France.
 Last year drug use provides a measure of recent 
drug use and is largely concentrated among young 
adults. An estimated 17.4 million young adults (aged 
15-34) used drugs in the last year (16.9 %), with about
twice as many males (21.6 %) as females (12.1 %)
reporting doing so.
 The prevalence of high-risk opioid use among adults 
(15-64) is estimated at 0.35 % of the EU population, 
equivalent to 1 million high-risk opioid users in 2019. 
 There were 510 000 clients in opioid substitution 
treatment in 2019 in the European Union. Opioid users 
accounted for 26 % of drug treatment requests. 
 Opioids were involved in 76 % of the fatal overdoses 




Drug use prevalence and trends
Drug use in Europe encompasses a wide range of substances. Among people who use drugs, 
polydrug consumption is common but challenging to measure, and individual patterns of use range 
from experimental to habitual and dependent consumption. Cannabis is the most commonly used 
drug – the prevalence of use is about five times that of other substances. While the use of heroin 
and other opioids remains relatively rare, these continue to be the drugs most commonly associated 
with the more harmful forms of use, including injecting. The extent of stimulant use and the types 
that are most common vary across countries, and evidence is growing of a potential increase 
in stimulant injecting. Use of all drugs is generally higher among males, and this difference is 
often accentuated for more intensive or regular patterns of use.
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Latest data on Europe’s drug situation
For the complete set of data and information on the methodology, see the accompanying online Statistical Bulletin.
Cannabis Cocaine
Heroin and other opioids
3.4 % 0.2 %
21.8 % 4.6 %
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LATEST DATA 
  Around 1.1 million seizures were reported in 2019 in 
Europe, with cannabis products most often seized. 
Most reported seizures involve small quantities of 
drugs confiscated from users, while a relatively small 
number of multi-kilogram consignments account 
for most of the total quantity of drugs seized. This 
underlines the fact that the detection or non-detection 
of small numbers of shipments can have a significant 
impact on overall totals.
  Indexed trends in the number of reported drug seizures 
in Europe between 2009 and 2019 show a diverse 
picture, but have been generally increasing. 
  The numbers of seizures of cannabis resin (−9 %) and 
heroin (−27 %) were lower in 2019 than in 2009. 
  The number of cocaine (+27 %), amphetamine (+40 %) 
and herbal cannabis (+72 %) seizures increased 
between 2009 and 2019, but at a slower pace than the 
quantities seized. This possibly indicates expanding 
production and transit activities, as well as increasing 
domestic consumer markets. 
  The largest increases in the number of 
seizures were seen for MDMA (+290 %) 
and methamphetamine (+182 %). 
  Indexed trends in the quantities of drugs seized 
in Europe indicate that there has been a general 
increase for all drugs except cannabis resin since 
2009 and more markedly since the mid-2010s. 
  Between 2009 and 2019, the largest increases in 
quantities seized have been for methamphetamine 
(+931 %), MDMA (+456 %) and cocaine (+279 %). 
Sizable consumer markets for these drugs exist 
in Europe, however, it is likely that increases in 
quantities seized reflect, at least partially, the larger 
role played by Europe as a place of production, export 
or transit for these drugs. The same factors may also 
explain the sizeable increase in seized quantities 
of amphetamine (+180 %).
  Heroin (+17 %) is the only drug for which quantities 
seized increased by less than 100 % over the period. 
  Cannabis resin (−19 %) is the only drug for which 
less was seized in 2019 than in 2009, while seizures 
of herbal cannabis increased markedly (+226 %). 
This probably reflects increasing herbal cannabis 
production in Europe. 
Drug supply and the market
Recent changes in Europe’s illicit drug market, largely linked to globalisation and 
new technology, include innovation in drug production and trafficking methods, 
the establishment of new trafficking routes and the growth of online markets. In 
the global context, Europe is an important market for drugs, supplied from both 
domestic production and trafficking from other world regions. South America, West 
Asia and North Africa are important source areas for illicit drugs entering Europe, 
while China is an important source country for new psychoactive substances, drug 
precursors and related chemicals. In addition, some drugs transit Europe en route to 
other continents. Europe is also a producing region for cannabis and synthetic drugs; 
cannabis production is mostly for European consumption, while synthetic drugs are 
manufactured for the European market and exported to other parts of the world.
15
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CANNABIS | Cannabis use remains stable at high levels, 
but increased THC content raises health concerns
Cannabis resin sold in Europe is now more potent than before, with a THC content 
on average between 20 % and 28 %, almost twice that of herbal cannabis. Cannabis 
products available in Europe now include high-THC content products and new forms 
of cannabis on the illicit market as well as a range of products containing cannabis 
extracts, but low levels of THC, sold commercially. Alongside these market changes, 
the numbers of first-time cannabis treatment entrants are increasing. Careful 
monitoring of this area is necessary to detect changes in cannabis problems and to 
understand the influence of shifts in the drug markets on them.  
LATEST DATA 
  In 2019, EU Member States reported 326 000 
seizures of cannabis resin amounting to 465 tonnes 
and 313 000 seizures of herbal cannabis amounting 
to 148 tonnes. Additionally, Turkey reported 6 200 
seizures of cannabis resin amounting to 28 tonnes 
and 64 000 seizures of herbal cannabis amounting 
to 63 tonnes.  
  Based on data from 26 countries that undertook a 
survey between 2015 and 2020, last year cannabis 
use among EU inhabitants aged 15-34 is estimated 
at 15.4 %, ranging from 3.4 % in Hungary to 21.8 % in 
France. When only 15- to 24-year-olds are considered, 
the prevalence of cannabis use is higher, with 19.2 % 
(9.1 million) having used the drug in the last year and 
10.3 % (4.9 million) in the last month.
  Of the countries that have conducted surveys since 
2018 and provided confidence intervals, 9 reported 
higher estimates than their previous comparable 
survey, 5 were stable and 2 reported a decrease. 
  Among the 24 EU Member States participating in the 
2019 ESPAD surveys of school students aged 15-16 
years, last year prevalence of cannabis use ranged 
from 7 % to 23 %, with a weighted average of 17.3 %. 
Overall, last year prevalence declined from a peak of 
20.4 % in 2011.
  General population surveys indicate around 1.8 % of 
adults aged 15-64 in the European Union are daily 
or almost daily cannabis users, using the drug on 
20  days or more in the last month, most of whom 
(61 %) are under 35.
  In 2019, around 111 000 people entered specialised 
drug treatment in Europe for problems related 
to cannabis use (35 % of all treatment demands); 
of those, about 62 000 were entering treatment 
for the first time. 
  In the 24 countries with available data, the overall 
number of first-time entrants for cannabis problems 
increased by 45 % between 2009 and 2019. Fifteen 
countries reported an increase between 2009 and 
2019 and two reported an increase in the last year 
(2018-19). 
  Overall, 51 % of first-time entrants to treatment 
for cannabis in 2019 reported daily use of the drug 
in the last month.
  Cannabis was the most common substance reported 
by the Euro-DEN Plus network in 2019. Cannabis was 
present in 26 % of acute drug toxicity presentations, 
usually with other substances, in the network’s 23 
hospitals in 17 countries.
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EU + 2 refers to EU Member States, Turkey and Norway. Price and potency of cannabis products: national mean values – minimum, 
maximum and interquartile range. Countries covered vary by indicator.
Cannabis use in last year among young adults (15-34), 2018/19 and previous survey; first-time treatment entries with cannabis 
as primary drug, 2018-19; presentations related to cannabis in Euro-DEN Plus hospitals, 2018-19.
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Apart from trends, data are for all treatment entrants with cannabis as primary drug. Trends in first-time entrants are based on 24 countries. Only countries with 
data for at least 8 of the 11 years are included in the trends graph. Missing values are interpolated from adjacent years. Due to changes in the flow of data at 
national level, data since 2014 for Italy are not comparable with earlier years.
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COCAINE | Record cocaine seizures are a worrying signal of 
potential for increased health harms
Cocaine remains the second most commonly used illicit drug in Europe, and 
consumer demand makes it a lucrative part of Europe’s drug trade for criminals. 
The record 213 tonnes of the drug seized in 2019 indicates an expanding supply in 
the European Union. Cocaine purity has been increasing over the last decade, and 
the numbers of people entering treatment for the first time have risen over the last 
5 years. These and other indicators signal the potential for increases in cocaine-
related problems.
LATEST DATA 
  In 2019, EU Member States reported 98 000 seizures 
of cocaine amounting to 213 tonnes (177 tonnes 
in 2018). Belgium (65 tonnes), the Netherlands 
(44  tonnes) and Spain (38 tonnes) together 
accounted for 69 % of the total quantity seized.
  The average purity of cocaine at retail level varied 
from 31 % to 91 % across Europe in 2019, with half 
the countries reporting an average purity between 
53 % and 68 %. The purity of cocaine has been 
on an upward trend over the past decade, and in 
2019 reached a level 57 % higher than the index 
year of 2009, while the retail price of cocaine has 
remained stable. 
  Cocaine was the substance most frequently submitted 
for testing to drug checking services in 14 European 
cities between January and June 2020. The average 
purity of cocaine samples was 60 % (69 % during the 
same period in 2019), with one in every three samples 
containing 80 % cocaine or more. 
  In the European Union, surveys indicate that nearly 
2.2 million 15- to 34-year-olds (2.1 % of this age 
group) used cocaine in the last year. 
  Among the 26 countries reporting surveys between 
2015 and 2020, last year prevalence of cocaine use 
among young adults aged 15-34 ranged from 0.2 % to 
4.6 %, with 8 countries reporting rates over 2.5 %.
  Of the 15 countries that have conducted surveys since 
2018 and provided confidence intervals, 8 reported 
higher estimates of last year use than their previous 
comparable survey and 7 had stable estimates.
  Of the 49 cities that have data on cocaine residues in 
municipal wastewater for 2019 and 2020, 19 reported 
an increase, 14 a stable situation and 16 a decrease. 
Increasing longer-term trends are observable for all 
the 10 cities with data covering the 2011 to 2020 
period. The most recent data indicate that cocaine 
is becoming more common in cities in the east of 
Europe, although detection levels remain low.
  First-time entries to specialised drug treatment for 
cocaine problems increased in 17 countries between 
2014 and 2019, and 12 countries reported an 
increase in the last year. 
  Most treatment entrants citing cocaine as their main 
problem drug are powder cocaine users: 45 000 
clients in 2019 or 14 % of all drug clients. Around 92 % 
of the 8 000 crack-related treatment entries in 2019 
were reported by 8 EU countries. 
  Cocaine was the second most common substance 
reported by Euro-DEN Plus hospitals in 2019, present 
in 22 % of acute drug toxicity presentations.
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COCAINE
Apart from trends, data are for all treatment entrants with cocaine as primary drug. Trends in first-time entrants are based on 24 countries. Only countries with data 
for at least 8 of the 11 years are included in the trends graph. Missing values are interpolated from adjacent years. Due to changes in the flow of data at national level, 
data since 2014 for Italy are not comparable with earlier years.
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Changes in cocaine indicators






EU + 2 refers to EU Member States, Turkey and Norway. Price and purity of cocaine: national mean values — minimum, maximum and interquartile range. 
Countries covered vary by indicator.
Cocaine use in last year among young adults (15-34), 2018/19 and previous survey; first-time treatment entries with cocaine as primary drug, 2018-19; 






















2009 2011 2013 2015 2017 2019
45+8+47+x 2.1+26+2+69+1+x
20
European Drug Report 2021: Trends and Developments
LATEST DATA 
  In 2019, EU Member States reported 34 000 seizures 
of amphetamine, amounting to 17.0 tonnes (8 tonnes 
in 2018), with the quantity seized increasing over the 
last four years. Significant increases were observed in 
Poland (1.7 tonnes) and Belgium (1.0 tonnes). Greece 
seized 9.6 tonnes of amphetamine in 2019 (including 
38 million ‘captagon’ tablets) and Turkey seized 2.8 
tonnes (11 million tablets, including large quantities 
of captagon tablets). Such tablets, named after a 
medicinal product, are likely destined for drug markets 
outside Europe.
  The average purity of amphetamine in the European 
Union at retail level varied from 13 % to 67 % in 
2019, with half the countries reporting an average 
purity between 20 % and 35 %. Among the countries 
consistently providing data on purity and price, 
the average purity of amphetamine has increased 
markedly over the past decade, while the price has 
remained relatively stable. 
  The average purity of amphetamine samples 
submitted for testing to drug checking services in 
10 European cities between January and June 2020 
was 35 % (37 % during the same period in 2019).
  In 2019, laboratories set up to convert amphetamine 
base oil into sulphate powder were dismantled 
in Germany (15) and Poland (4). Denmark and 
Norway indicated that such facilities were operating 
in their territories.
  Amphetamine and methamphetamine are grouped 
together as amphetamines in certain data sets. 
Surveys from 25 countries conducted between 2015 
and 2020 suggest that 1.4 million young adults (15-34) 
used amphetamines during the last year (1.4 % of this 
age group). National prevalence estimates range from 
zero in Portugal to 4.1 % in the Netherlands. 
  Of the 15 countries that have conducted surveys 
since 2018 and provided confidence intervals, 
4 reported higher estimates than their previous 
comparable survey, 10 reported a stable trend and 
1 a lower estimate.
  Of the 48 cities with data on amphetamine residues in 
municipal wastewater for 2019 and 2020, 20 reported 
an increase, 9 a stable situation and 19 a decrease. 
The 9 cities with data from 2011 to 2020 showed 
a diverse picture, with increasing trends in 4.
  More than 13 000 clients entering specialised drug 
treatment in Europe in 2019 reported amphetamine 
as their primary drug, of whom about 6 000 were 
first-time clients. Amphetamine users account for at 
least 15 % of first-time treatment entrants in Bulgaria, 
Latvia, Poland and Finland. 
  About 11 % of amphetamine clients reported injecting 
as the main route of administration, while 65 % 
reported sniffing and 16 % reported oral consumption 
of the drug. 
  Amphetamine was the fourth most common 
substance reported by Euro-DEN Plus hospitals 
in 2019, present in 12 % of acute drug 
toxicity presentations.
AMPHETAMINE | Stable amphetamine demand makes domestic 
production near consumers profitable
Amphetamine, Europe’s second most consumed stimulant drug after cocaine, is 
produced near consumer markets in the European Union, mainly in the Netherlands, 
Belgium and Poland. Final production, converting liquid base oil into amphetamine 
sulphate, happens in some additional countries. Alongside the health risks from 
high-risk amphetamine use, dangerous domestic production laboratories remain 
a challenge for law enforcement.
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AMPHETAMINE
Apart from the map, data are for all treatment entrants with amphetamine as primary drug. Data for Sweden and Norway relate to clients citing a stimulant other than 
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Changes in amphetamine indicators




EU + 2 refers to EU Member States, Turkey and Norway. Price and purity of amphetamine: national mean values — minimum, maximum and interquartile 
range. Countries covered vary by indicator.
Amphetamines (including methamphetamine) use in last year among young adults (15-34), 2018/19 and previous survey; first-time treatment entries with 
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LATEST DATA 
  In 2019, EU Member States reported 10 000 seizures 
of methamphetamine amounting to 2.9 tonnes, up 
from 0.6 tonnes in 2018. Spain (1.6 tonnes, originating 
in Mexico), the Netherlands and Poland (0.5 tonnes 
each) seized the largest quantities. Slovakia reported 
seizing 1.5 tonnes of methamphetamine originating in 
Mexico in 2020. 
  In 2019, the average purity of methamphetamine 
ranged from 16 % to 94 %, with half of the 12 
countries reporting an average purity between 32 % 
and 74 %. It is not possible to analyse trends over time 
for methamphetamine. However, the overall average 
purity and price in 2019 were comparable to the 
values reported in 2009. 
  Methamphetamine accounted for only 2 % (46) 
of all samples submitted to drug checking services 
in 13 European cities during the first half of 2020. 
  Alongside the large seizures reported by Spain 
and Slovakia as originating in Mexico, Belgium 
has reported that Mexico is an important source 
country for methamphetamine seized since 
2017. Austria and Germany reported in 2019 that 
methamphetamine is trafficked by postal packages 
(air freight) from Mexico to Europe. 
  Czechia reports that domestically available 
methamphetamine is mainly produced in Czechia, 
while some originates in the Netherlands, Belgium 
and Poland. 
  Methamphetamine in Europe appears in powder 
and crystalline form. Injecting or smoking of 
methamphetamine is reported among various sub-
groups of people who use drugs, including problem 
drug users and people in the ‘chemsex’ scene.
  Three countries have recent estimates of high-risk 
methamphetamine use, ranging from 0.55 per 
1 000 population (corresponding to 330 high-risk 
users) in Cyprus to 5.04 per 1 000 (34 600 high-risk 
users) in Czechia.
  Of the 50 cities that have data on methamphetamine 
residues in municipal wastewater for 2019 and 2020, 
15 reported an increase, 14 a stable situation and 
21 a decrease.
  About 9 200 clients entering specialised 
drug treatment in Europe in 2019 reported 
methamphetamine as their primary drug, of whom 
about 4 500 were first-time clients.
  Treatment entrants reporting methamphetamine as 
their main problem drug are concentrated in Czechia, 
Germany, Slovakia and Turkey, which together account 
for 90 % of the 9 200 methamphetamine clients 
reported in 2019. 
  Methamphetamine was the twelfth most 
common substance reported by Euro-DEN Plus 
hospitals in 2019, present in 2.5 % of acute drug 
toxicity presentations.
METAMPHETAMINE | Methamphetamine production and 
trafficking highlights potential for increased use in Europe
Use of methamphetamine in Europe has historically been restricted to Czechia, and 
more recently Slovakia, where it accounts for a large share of drug-related harms. 
Demand for the drug within Europe remains small, but production and trafficking 
shifts highlight the risk of increased consumption. While smaller production sites 
are detected annually in Europe, large-scale laboratories are also being found, and 
large quantities of methamphetamine are being transhipped through the European 
Union to other markets. These changes are linked to collaborations between European 
and Mexican criminal groups. Given the potential for additional supplies of the drug 
within Europe to result in increased use and the health risks associated with it, careful 
monitoring of developments is required.
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Changes in methamphetamine indicators




EU + 2 refers to EU Member States, Turkey and Norway. Price and purity of methamphetamine: national mean values – minimum, maximum and interquartile 
range. Countries covered vary by indicator.
First-time treatment entries with methamphetamine as primary drug, 2018-19; wastewater analysis (SCORE) 2019-20; presentations related  
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European Drug Report 2021: Trends and Developments
LATEST DATA 
   In 2019, the average drug content of MDMA 
(ecstasy) tablets seized in Europe ranged from 118 
to 210 milligrams of MDMA per tablet, with half the 
countries reporting an average between 161 and 193 
milligrams. The average quantity of MDMA in tablets 
has increased by 149 % since 2009.
  The purity of MDMA powders ranged from 34 % to 
94 %, with half the countries reporting an average 
between 58 % and 88 %.
  Seizures of MDMA powder in the European Union 
increased from 0.3 tonnes in 2016 to 2.2 tonnes in 
2018 and, this level was maintained in 2019. The 
4.6 million MDMA tablets seized in 2019 confirms the 
general upward trend observed since 2009. 
  In 2017, 2018 and 2019, annual seizures reported by 
Turkey of more than 8 million MDMA tablets exceeded 
the total amounts reported in the European Union. 
  Between January and June 2020, the average amount 
of MDMA per tablet tested by drug checking services 
in 10 European cities was 177 milligrams (180 mg 
during the same period in 2019). Services in five 
cities reported individual tablets containing between 
270 and 366 milligrams of MDMA. The average purity 
of MDMA powder reported in 2020 was 81 % (88 % 
during the same period in 2019). 
  The number of dismantled MDMA laboratories 
reported in the European Union was 28 in 2019  
(23 in 2018).
  Surveys from 26 countries conducted between 
2015 and 2020 suggest that 2 million young adults 
(15-34) used MDMA in the last year (1.9 % of this age 
group), ranging from 0.2 % in Portugal to 8.5 % in the 
Netherlands. Prevalence estimates for those aged 15-24 
years are higher, with 2.2 % (1.0 million) estimated to 
have used MDMA in the last year.
  No overall trend emerges from the data on MDMA use. 
Of the 15 countries that undertook surveys since 2018 
and provided confidence intervals, 7 reported higher 
estimates than their previous comparable survey, and 
8 reported stable estimates.
  Of the 49 cities that have data on MDMA residues in 
municipal wastewater for 2019 and 2020, 18 reported 
an increase, 7 a stable situation and 24 a decrease. 
Of the 9 cities with data for both 2011 and 2020, 
7 had higher MDMA loads in 2020 than in 2011. 
Among these cities, MDMA loads are particularly high 
in Amsterdam, likely reflecting its position as a tourism 
and nightlife destination.
  MDMA was the sixth most common drug reported by 
Euro-DEN Plus hospitals in 2019, present in 9.5 % of 
acute drug toxicity presentations. Six of the 26 in-
hospital deaths recorded involved MDMA.
MDMA | Risks to health from supply of high-strength  
MDMA products  
Europe remains an important source of MDMA products that supply the global 
market. The number of MDMA laboratories dismantled by law enforcement authorities 
in the European Union continues to rise. Alongside increases in the average MDMA 
content in tablets and the purity of powders, products containing hazardous levels 
of MDMA are being detected, putting users at risk and challenging existing prevention 
and harm reduction responses. Preliminary data for 2020, however, suggest a 
possible decline in use during periods of lockdown. 
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EU + 2 refers to EU Member States, Turkey and Norway. Price and purity 
of MDMA: national mean values – minimum, maximum and interquartile 
range. Countries covered vary by indicator. Available data do not permit 
time trend analysis of MDMA content. 
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Mean daily amounts of MDMA in milligrams per 1 000 population. Sampling was carried out in selected European cities over a week  
in each year from 2011 to 2020. Source: Sewage Analysis Core Group Europe (SCORE).
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LATEST DATA 
  At the end of 2020, the EMCDDA was monitoring 
around 830 new psychoactive substances, 46 of 
which were first reported in Europe in 2020. 
  Since 2015, every year around 400 previously reported 
new psychoactive substances are detected in Europe.
  In 2019, EU Member States accounted for 22 070 of 
the 34 800 seizures of new psychoactive substances 
reported in the European Union, Turkey and Norway.
  In 2019, EU Member States reported seizures 
amounting to 2.0 tonnes of new psychoactive 
substances, mainly powders, or 2.7 tonnes taking 
Turkey and Norway into account. 
  Synthetic cannabinoids and cathinones accounted 
for almost 60 % of the number of seizures reported in 
2019 by EU Member States, with arylcyclohexylamines 
(largely ketamine) accounting for a further 10 %.
  A total of 209 new synthetic cannabinoids have been 
detected in Europe since 2008, including 11 reported 
for the first time in 2020. In 2019, EU Member States 
accounted for approximately 6 500 of the 18 700 
seizures reported in the European Union, Norway 
and Turkey, and 200 of the 900 kilograms seized. 
  The 67 new synthetic opioids detected between 
2009 and 2020 include 10 first reported in 2020. 
In 2019, approximately 430 seizures of new opioids 
were reported, amounting to 17 kilograms of material. 
EU Member States accounted for 1 240 of the 1 334 
new benzodiazepines seizures reported in 2019.
  Based on data from countries that undertook a survey 
between 2015 and 2018, last year prevalence of new 
psychoactive substance use among adults (15-64) 
ranged from 0.1 % to 1.4 %, with an average of 0.6 % 
across the 15 countries with data for this age group. 
Among young adults (15-34), last year prevalence 
ranged from 0.2 % to 3.2 %, with an average of 1.1 % 
across the 12 countries with data.
  Twenty-two EU Member States, representing 
61.6% of the EU population of 15- to 16-year-olds, 
participated in both the 2015 and 2019 ESPAD 
school surveys. Among these countries, last year 
prevalence of use of new psychoactive substances 
among 15- to 16-year-olds in 2015 ranged from 0.8 % 
to 8.3 %, with a weighted average of 3.8 %. In 2019, 
last year prevalence ranged from 0.6 % to 4.9 %, with 
a weighted average of 2.4 %.
  Three EMCDDA risk assessments in 2020 addressed 
two synthetic cannabinoids, MDMB-4en-PINACA 
and 4F-MDMB-BICA (associated with 21 deaths in 
Hungary in 2020), and a potent non-fentanyl synthetic 
opioid, isotonitazene.  
NEW PSYCHOACTIVE SUBSTANCES | Harmful potent new 
psychoactive substances continue to emerge
Over 400 new psychoactive substances were detected on Europe’s drug market 
in 2019. Potent new synthetic cannabinoids and new synthetic opioids continued 
to emerge, posing health and social threats. Reports of cannabis adulterated with new 
synthetic cannabinoids, such as MDMB-4en-PINACA, being sold to unsuspecting users 
highlight the new and potentially growing risks of the inadvertent consumption of these 
potent substances. New dosage forms for synthetic cannabinoids, including e-liquids 
and impregnated papers, are increasingly available on the drug market.
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NEW PSYCHOACTIVE SUBSTANCES
Number of substances monitored by the EU Early 









on the market each year
First-time detections of new substances 
detected – selected categories
 Cannabinoids   Cathinones   Other substances  
 Phenethylamines   Opioids   Tryptamines  
 Arylalkylamines   Benzodiazepines   Arylcyclohexylamines  
 Piperazines   Plants and extracts   Piperidines and pyrrolidines 













































































































































































































































2017 Poisoning leading to death
9 deaths reported by Hungary (8) and Sweden (1)
4F-MDMB-BICA Synthetic cannabinoid 2020
Poisoning leading to death





Acute respiratory depression leading to death
1 death reported by Germany 
22 deaths reported by third countries since August 2019
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National estimates of last year use of new psychoactive substances
Trends in number of seizures reported 
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LATEST DATA 
  Seizures of LSD, DMT, hallucinogenic mushrooms, 
ketamine and GHB (including its precursor GBL) 
are not consistently monitored in Europe, but some 
information is available from reports to different 
EMCDDA monitoring systems. Data for these 
substances are incomplete and often divergent, 
highlighting the need for improved monitoring 
in this area.
  From the limited information available, in 2019, about 
2 400 seizures of LSD (lysergic acid diethylamide), 
amounting to almost 115 000 units, were reported 
in Europe. Nineteen countries reported 950 seizures 
of hallucinogenic mushrooms, amounting to 
55 kilograms. Sixteen EU countries reported about 
300 seizures of DMT (dimethyltryptamine), amounting 
to 89 kilograms and almost 75 000 units. 
  Seizures of ketamine were reported by at least 16 EU 
countries, with the total quantity seized estimated to 
be between 250 and 600 kilograms. 
  Large seizures of GHB (gamma-hydroxybutyrate) or its 
precursor GBL (gamma-butyrolactone) were reported 
by 18 countries, amounting to 48 tonnes and just under 
500 litres. Due to the extensive use of GBL for industrial 
purposes, the data are challenging to interpret.
  Among young adults (15-34), the most recent national 
surveys report last year prevalence estimates for LSD 
and hallucinogenic mushrooms equal to or less than 
1 % for both substances. Exceptions to this include 
Finland (2.0 % in 2018), Estonia (1.6 % in 2018, 16-34) 
and the Netherlands (1.1 % in 2019) for hallucinogenic 
mushrooms, and Finland (2.0 % in 2018) and Estonia 
(1.7 % in 2018, 16-34) for LSD.
  National estimates of the prevalence of ketamine and 
GHB use in adult and school populations are low, with 
Denmark reporting last year prevalence of ketamine 
use among young adults (16-34) of 0.6 % in 2017, and 
Romania 0.8 % in 2019. The Netherlands reports that 
ketamine has become a more common drug among 
young people in the nightlife scene. 
  GHB was the fifth most common drug reported by 
Euro-DEN Plus hospitals in 2019, present in 10.6 % 
of acute drug toxicity presentations and 27 % of 
critical care admissions. LSD and ketamine were 
each present in 1.7 % of the acute drug toxicity 
presentations reported by Euro-DEN Plus. 
LSD, DMT, MUSHROOMS, KETAMINE AND GHB | Are less commonly 
used drugs posing increasing challenges for public health?
LSD, DMT, hallucinogenic mushrooms, ketamine and GHB (including its precursor 
GBL) are available in Europe, but these substances are poorly monitored, and this 
limits our understanding of their use and impact on public health. There are signs that 
interest in some of these substances may be growing and that, for some, availability 
may be increasing in Europe. In particular, there are concerns about the possible risks 
associated with chronic harms (e.g. regarding ketamine) and risks associated with more 
intensive patterns of use in certain niche settings and contexts, such as the use of GHB 
in the ‘chemsex’ scene. There is a growing need for greater investment in monitoring to 
support the development of harm reduction and other interventions appropriate to the 
settings and contexts in which these drugs are being consumed. 
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LATEST DATA 
  EU Member States reported 26 000 heroin seizures 
amounting to 7.9 tonnes in 2019. Large quantities 
were reported by Belgium (1.9 tonnes), Bulgaria 
(0.8 tonnes), France (1 tonne), the Netherlands 
(1.3 tonnes) and Slovenia (0.8 tonnes).
  Turkey seized over 20 tonnes of heroin in 2019, 
the largest amount in a decade.
  The average purity of heroin at retail level varied 
from 11 % to 51 % in 2019, with half the countries 
reporting an average purity between 18 % and 31 %. 
Indexed trends show that the average purity of heroin 
rose by 23 % between 2009 and 2019, while its price 
dropped 17 %.
  Almost 13 000 seizures of other opioids, amounting 
to over 1.7 tonnes and large numbers of tablets, were 
reported in 2019. Seizures of fentanyl derivatives in 
2019 amounted to 15 kilograms, more than double the 
6 kilograms seized in 2018. The Netherlands reported 
a seizure of 1 kilogram of fentanyl in 2020.
  National prevalence estimates range from less than 
1 to more than 7 high-risk opioid users per 1 000 
population aged 15-64. Overall, this translates into an 
estimated 0.35 % of the EU population, or 1 million 
high-risk opioid users in 2019. The four most populous 
countries in the European Union (Germany, Spain, 
France and Italy) account for more than two thirds 
(68 %) of this estimate.
  In 2019, use of opioids was reported as the main 
reason for entering specialised drug treatment by 
84 000 clients, or 27 % of all those entering drug 
treatment in Europe. Of these, almost 20 000 were 
first-time entrants.
  Heroin was the primary drug for 13 600 (79 %) of the 
17 300 first-time entrants for whom the opioid was 
reported, a relatively stable number when compared 
with the previous year. 
  The number of first-time heroin clients has fallen 
by more than half from a peak observed in 2009. 
Between 2018 and 2019, the number of first-time 
treatment entrants for primary heroin use decreased 
in 8 countries out of the 20 with available data.
  Heroin was the third most common drug reported by 
Euro-DEN Plus hospitals in 2019, present in 16 % of 
acute drug toxicity presentations. Opioids were found 
in 10 of the 26 in-hospital deaths recorded, usually 
with other drugs. 
HEROIN AND OTHER OPIOIDS | Large heroin seizures signal 
potential for increased use and harms
With large quantities of heroin seized in Europe in 2018 and 2019, there is increasing 
concern about the impact a rising supply may have on rates of use. As in 2018, large 
individual shipments were detected in 2019 in ports in European countries, including 
Belgium, the Netherlands and Slovenia, reflecting a diversification of heroin trafficking 
beyond land routes. In Europe, treatment entry and other indicators suggest that 
those using heroin are an ageing and diminishing group. However, increased 
surveillance is required to detect any changes in the use of a drug that continues to 
be associated with a large share of the burden of illness and death linked with drug 
use in Europe.
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HEROIN
Apart from trends, data are for all treatment entrants with heroin as primary drug. Data for Germany, Sweden and Norway are for entrants with 
‘opioids’ as primary drug. Trends in first-time entrants are based on 24 countries. Only countries with data for at least 8 of the 11 years are included 
in the trends graph. Missing values are interpolated from adjacent years. Due to changes in the flow of data at national level, data since 2014 for Italy 
are not comparable with earlier years.
 France  Germany  Spain  
 Italy  Other countries
 Injecting, 31 %
 Smoking/inhaling, 41 %
 Eating/drinking, 1 %
 Sniffing, 25 %












2009 2011 2013 2015 2017 2019
Trends in first-time entrantsCharacteristics
Number of countries or hospitals reporting a change since the last data collection
Frequency of use 
in the last month
Route of administration
19 % 81 %
23Mean age at first use Mean use 6 days per week
Daily




Not used in the 
last 30 days






































EU + 2 refers to EU Member States, Turkey and Norway. Price and purity of ‘brown heroin’: national mean values – minimum, maximum and interquartile range.  
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LATEST DATA 
  Cannabis: EU Member States reported seizures 
of 3.7 million cannabis plants in 2019. Seizures 
of plants are an indicator of domestic production, 
which is increasingly sophisticated. Reports are 
emerging of small-scale production of highly potent 
cannabis extracts.
  Heroin: Four heroin production sites were dismantled 
in the Netherlands in 2019. In addition, 10 seizures 
of acetic anhydride, the precursor chemical needed 
for heroin manufacture, amounting to 26 000 litres, 
were reported by 6 EU Member States (5 in the 
Netherlands and 1 in each of Belgium, Bulgaria, 
Estonia, Poland and Romania). Eleven stopped 
shipments of acetic anhydride were also reported 
by 3 EU Member States, amounting to almost 
7 000 litres, indicating further attempts to divert 
this chemical from legitimate supply.
  Cocaine: In 2019, Spain reported dismantling 
5 cocaine laboratories (3 for secondary extraction, 2 for 
transformation), while Belgium reported recovering 
extraction equipment. In 2020, an extraction facility 
with an estimated daily production capacity of between 
150 and 200 kilograms of cocaine was dismantled 
in the Netherlands. 
  Amphetamine: 14 500 litres of BMK and 31 tonnes 
of MAPA (up from 7 tonnes in 2018) – chemicals used 
to manufacture amphetamines – were seized in the 
European Union in 2019. 
  Methamphetamine: Seven EU Member States 
reported the dismantling of 267 methamphetamine 
laboratories in 2019, among which were large-scale 
facilities in Belgium (3) and the Netherlands (9 in 
2019 and an additional 32 in 2020), sometimes 
involving European and Mexican gangs. Seizures 
of ephedrine and pseudoephedrine amounting to 
640 kilograms (both powders and tablets) were 
reported by 10 other EU Member States in 2019.
  MDMA: Four EU Member States reported the 
dismantling of 28 MDMA laboratories (23 in 2018) 
in 2019: the Netherlands (20), Belgium (5), Germany  
(2, 1 of which produced MDA) and Poland (1). 
  Seizures of MDMA precursors decreased to 
almost 7 tonnes in 2019 (16 tonnes in 2018), with 
no apparent corresponding reduction in MDMA 
production. 
  GHB: In 2019, the dismantling of 9 laboratories 
involved in the production of GHB from GBL was 
reported by the Netherlands (7) and Germany 
(2), with Belgium and Estonia also reporting 
the detection of production sites.
  New psychoactive substances: Five sites involved 
in the production of synthetic cathinones were 
dismantled in 2019: 1 in the Netherlands and 4 in 
Poland. Seizures of the synthetic cathinone precursor 
2-bromo-4-methylpropiophenone amounted to 
432 kilograms in 2019 (50 kilograms in 2018), 
of which 428 kilograms was seized in Belgium, 
Germany and the Netherlands.
  In 2019, more than 33 kilograms of N-phenethyl-
4-piperidone (NPP), a fentanyl precursor, was 
seized in 2 separate cases in Estonia. Seizures of 
non-controlled fentanyl precursors were reported by 
Belgium (1 kilogram of 4-piperidone monohydrate) 
and Germany (0.1 kilogram of 1-anilinopiperidine). 
PRODUCTION AND PRECURSORS | Organised crime groups 
intensify illegal drug production within Europe
In 2019, more than 370 illegal drug production laboratories were dismantled in Europe. 
The increased number of facilities detected and the manufacturing of a wider range of drugs 
reflect the scaling-up of efforts by criminals to produce drugs closer to consumer markets in 
order to evade anti-trafficking measures. This shift brings with it threats to local environments 
and risks to the health of people using the drugs. Combating drug production presents 
legislators with the complex regulatory challenge of controlling precursor chemicals and 
law enforcement agencies with a hazardous phenomenon to tackle.
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Drug type What is Europe’s role in 
production?
What is the focus of control 
measures in Europe on the 
production and movement of 
drugs?
What are the main challenges for law 
enforcement? 
Cannabis resin Mostly imported; 
some resin production 
in Europe
Supply chain (production, 
trafficking and distribution)
Variety of smuggling routes and methods
Smuggling through unstable territories
Use of various maritime vessels (e.g. speedboats), 
civil aviation and unmanned aircraft
Herbal cannabis Produced in Europe for 
European markets
Cultivation sites
Supply chain (production, 
trafficking and distribution)
Localised and dispersed cultivation sites near 
consumer markets to minimise detection risks
Retail-level sales on darknet drug markets
Distribution through postal, parcel and 
delivery systems
Cocaine Imported; limited 
production in Europe
Supply chain (production, 
trafficking and distribution)
Precursor control
Processing facilities such as 
crystallisation and secondary 
extraction labs 
Continued use of scheduled precursors 
in production
Variety of smuggling routes and methods
Use of container transport
Corruption of port and other authorities
Heroin Imported; limited 
production in Europe; 
source region of diverted 
precursors




Continued diversion of scheduled precursors
Variety of smuggling routes and methods
Use of container transport
Amphetamine Produced in Europe 
for European and to 
a lesser extent Middle 
Eastern markets
Precursor control
Production facilities, including 
waste dumping sites
Supply chain (production, 
trafficking and distribution)
Use of novel chemicals in manufacturing
Signs of localised processing and production 




Production facilities, including 
waste dumping sites
Supply chain (production, 
trafficking and distribution)
Continued use of scheduled precursors 
in production 
Use of novel chemicals in manufacturing
Increasing role of organised crime, including from 
outside the EU




Production facilities, including 
waste dumping sites
Supply chain (production, 
trafficking and distribution)
Continued use of scheduled precursors 
in production
Use of novel chemicals in manufacturing
Retail-level sales on darknet drug markets






production in Europe; 
processing in Europe
Supply chain (production, 
trafficking and distribution)
Production facilities
Detection of production sites
Diverse unscheduled production materials
Illegal drug production in Europe
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LATEST DATA 
  In 2019, an estimated 1.5 million drug law offences 
were reported in the European Union, an increase 
of almost a quarter (24 %) since 2009. Most of 
these offences (82 % or 1.2 million) related to use 
or possession for personal use. 
  With approximately 617 000 reported offences 
in 2019, cannabis accounted for three quarters 
of the use or possession offences for which the 
drug is known. 
  Of the estimated 1.5 million drug law offences, the 
drug mentioned in the offence is reported in just 
over 1 million offences, of which 826 000 were for 
possession or use, 176 000 were for supply related 
offences and 7 500 were for other types of offence. 
  In 2019, the 76 000 use or possession offences 
involving cocaine continued an upward trend observed 
during the previous 3 years.
  With almost 55 000 reported cases in 2019, offences 
for use or possession of amphetamines dropped from 
the 10-year high level reached in 2018.
  Offences for use or possession of MDMA continued 
to increase in 2019, with just under 17 000 reported, 
accounting for 2 % of use-related offences.
  Offences for use or possession of heroin continued 
to fluctuate around the relatively low level reached in 
2013, with approximately 23 000 reported in 2019.
  Overall, the number of drug supply offences in the 
European Union has increased by 13 % since 2009, 
with an estimate of about 209 000 cases in 2019. 
  Cannabis dominates, with about 101 000 
offences reported in 2019, accounting for 57 % 
of supply offences. 
  Supply offences for MDMA have been rising since 
2011, with 7 000 reported in 2019. Cocaine supply 
offences have increased mainly in the last three years, 
with approximately 34 000 reported in 2019. The 
situation for heroin was relatively stable over the same 
period and approximately 10 000 supply offences 
were reported in 2019. 
DRUG LAW OFFENCES | Drug law offences increase, with 
cannabis possession and supply predominant 
Drug law offences statistics provide insights on the implementation of drug laws. 
They are driven primarily by law enforcement activities, and therefore are influenced 
by factors that affect these activities and by registration and reporting practices. 
Thus, while the predominance of cannabis in both supply and possession offences 
reflects the drug’s leading position among illicit substances, it also attests to the policy 
importance of this drug. 
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DRUG LAW OFFENCES
Data are for offences for which the drug has been reported. Data for amphetamine supply offences are limited and do not allow for EU trend analysis.
Drug law offences in the European Union related to drug use or possession for use or drug supply: 
indexed trends and reported offences in 2019
Possession/use offences Number of offences Supply offences
 Heroin   Cannabis   Cocaine   Amphetamines   MDMA   Other substances
Indexed trends (million) Indexed trends
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LATEST DATA 
  Only 15 countries have estimates of the prevalence of 
injecting drug use since 2015, where they range from 
less than 1 case per 1 000 population aged 15-64 in 
Belgium, Greece, Spain, Hungary and the Netherlands, 
to more than 10 in Estonia. Opioids are reported 
as the main injected drugs in the majority (11) of 
these countries. 
  Among first-time clients entering specialised drug 
treatment in 2019 with heroin as their primary 
drug, 23 % reported injecting as their main route 
of administration, down from 35 % in 2013. 
  In this group, levels of injecting vary between 
countries, from less than 10 % in Denmark, Spain 
and Portugal to 80 % or more in Czechia, Latvia 
and Romania. 
  Injecting is reported as the main route of 
administration by less than 1 % of first-time cocaine 
clients, 3 % of first-time amphetamine clients and  
31 % of methamphetamine clients. 
  The overall picture for methamphetamine, however, is 
influenced by Czechia, which accounts for more than 
70 % of first-time methamphetamine clients injecting 
the drug in Europe. 
  Considering the four main injected drugs together, 
injecting as the main route of administration among 
first-time entrants to treatment in Europe has declined 
from 22 % in 2013 to 10 % in 2019.
  Analysis of 1 166 used syringes collected by the 
ESCAPE network of seven European cities in 2020 
showed that in four cities over half of the syringes 
contained stimulants: cathinones in Budapest and 
Paris; amphetamines in Oslo and Prague.
  Heroin was also found in the majority of syringes 
in Budapest and Oslo, while opioid substitution 
medications were commonly detected in syringes 
in Helsinki (buprenorphine), Prague (buprenorphine) 
and Vilnius (methadone).
  Fentanyl or carfentanil was detected in more than 
40 % of syringes from Riga. 
  A third of all syringes contained two or more drugs, 
indicating polydrug use or re-use of injecting material. 
The most frequent combination was a mix of stimulant 
and opioid.
INJECTING DRUG USE | First-time treatment clients for heroin 
use continue to inject less 
Although injecting drug use has been declining in Europe for the past decade, 
it remains a major cause of drug-related harms. Considerable differences exist 
between countries, both in levels of injecting drug use and in injecting practices and 
substances used. While primarily connected to heroin use, other drugs, including 
amphetamines, cocaine, synthetic cathinones, opioid substitution medications and 
other medicines, are also injected. With high-risk drug consumption practices still a 
significant problem, the provision of effective treatment and early detection of shifts 
in the substances available on the drug market remain key drug policy issues for 
targeting resources. 
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Injecting among first-time treatment entrants with heroin, cocaine, amphetamine or methamphetamine 












Opioids, stimulants, hallucinogens, hypnotics and sedatives
Heroin
Heroin
Cases per 1 000 population aged 15-64 (lower and upper limits)
Trends in injecting among first-time treatment entrants are based on 23 countries. Only countries with data for at least 5 of the 7 years are included in the trends 
graph. Missing values are interpolated from adjacent years. 
Injecting drug use: most recent estimates of prevalence of injecting any drug in the last year and main drug injected
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LATEST DATA 
  An estimated 849 new HIV diagnoses and 266 new 
AIDS cases attributable to injecting drug use were 
notified in the European Union in 2019. Overall, 5.5 % 
of the new HIV diagnoses were attributed to injecting 
drug use.
  While the overall trend in HIV incidence has been 
decreasing in the last decade, local outbreaks 
mostly associated with stimulant injecting (cocaine 
and synthetic cathinones) have been documented 
in Europe.
  Subnational seroprevalence studies conducted in 
2017-19 in Estonia, Lithuania, Poland and Romania 
indicated a prevalence of HIV antibodies among 
people who inject drugs greater than 20 %.
  EU data show that more than half of the new HIV 
diagnoses attributed to drug injecting in 2019 were 
diagnosed late – when the virus had already begun 
to damage the immune system.
  France, Luxembourg and Austria reported data in 
2018 for all stages of the continuum of care for people 
who inject drugs living with HIV. Of these, only France 
had met the related Fast-Track targets to end  
HIV/AIDS by 2030. 
  The latest data suggest that the incidence of HCV 
transmission is high among people who inject drugs. 
In 2018-19, HCV antibody prevalence in national 
samples of people who inject drugs varied from 15 % 
to 86 %, with 7 of the 15 countries with national 
data reporting rates in excess of 50 %. Among the 
6 countries reporting local or national data on current 
infections among people who inject drugs, measured 
by HCV-RNA (or antigen) tests in 2013-19, the average 
prevalence was 44 %, ranging from 15 % in Belgium to 
64 % in Sweden.
  In the 7 countries with national data for 2018-19, an 
average of 4 % (ranging from 0.4 % in Latvia to 8 % 
in Spain) of people who inject drugs were estimated 
to be currently infected with HBV. An effective HBV 
vaccine is available.
  In 2019, people who inject drugs were reported to 
face institutional restrictions in accessing direct-acting 
antiviral HCV treatment in 7 EU Member States. 
  In 2019, Luxembourg and Norway reported meeting 
the World Health Organization’s 2020 targets for 
200 syringes per person who injects drugs per year 
and 40 % of the population of high-risk opioid users 
on opioid substation treatment.
  Integrating testing and treatment of HCV, HBV and HIV 
within harm reduction and drug treatment services 
is key to reaching the continuum of care targets for 
people who inject drugs.
DRUG-RELATED INFECTIOUS DISEASES | Scaling up treatment 
and prevention is required to reach HIV and HCV Sustainable 
Development Goals 
People who inject drugs have a higher risk of contracting infections such as the 
human immunodeficiency virus (HIV) and the hepatitis C virus (HCV) through shared 
drug use material. The European Union and its Member States support the 2030 
Sustainable Development Goals to end the HIV/AIDS epidemic and combat viral 
hepatitis. Increased access to integrated testing and treatment for HIV, HBV and HCV 
within harm reduction and drug treatment services is an important part of reaching 
the Fast-Track commitments on HIV/AIDS and the continuum of care targets on HCV 
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DRUG-RELATED INFECTIOUS DISEASES
Trends in drug-related HIV: EU and selected countries
Cases per million population
 Latvia  Lithuania  Estonia  Greece 
 Bulgaria  Romania  European Union












New AIDS cases attributable to injecting drug use
12 %
Needle and syringe distribution and opioid substitution treatment coverage in relation to WHO 2020 targets, 
2019 or latest available estimate
849
HCV current infections among people  
who inject drugs 2018/19
15-64 % in subnational samples in 4 countries
HBV current infections, national data 
for 2018-19  
an average of 4 % (0.4-8 %) among people  
who inject drugs 
HCV antibody prevalence among people who 
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The coverage is based on the latest national estimates of injecting drug use and high-risk opioid use matched by harm reduction activity data (within a maximum 
of 2 years). The estimate of coverage of opioid substitution treatment for Belgium is derived from a subnational study conducted in 2019.
15 % to 86 %
in 15 countries
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DRUG-INDUCED DEATHS | Overdose deaths driven by opioids 
and other drugs highlight need for service development  
High-risk substance use and polydrug use continue to fuel drug-induced deaths 
in Europe. Most deaths directly linked to drug use involve opioids, mainly heroin in 
conjunction with other drugs, while stimulants like cocaine and the amphetamines and, 
more recently, synthetic cannabinoids are now of concern. Increases in deaths among 
different age groups, including teenagers in some countries and those over 50, highlight 
the diversity of the challenge facing service providers and existing models of provision.
LATEST DATA
 It is estimated that at least 5 141 overdose deaths, 
involving illicit drugs, occurred in the European 
Union in 2019, representing an increase of 3 % 
compared with 2018. This total rises to an estimated 
5 769 deaths if Norway and Turkey are included, 
representing a slight decrease in relation to the revised 
estimate of 5 920 in 2018. In most southern and 
eastern European countries, this pattern is reversed, 
with increases in the number of overdose deaths when 
compared with 2018.
 The mortality rate due to overdoses in the European 
Union in 2019 is estimated at 14.8 deaths per million 
population aged 15-64. Over three quarters (77 %) of 
overdose deaths occurred among males; a rate of 23.7 
cases per million males. Among males, those aged 
35-39 were the most affected, with a mortality rate of 
37.7 deaths per million, more than double the average 
seen for all ages.
 Opioids, including heroin or its metabolites, often in 
combination with other substances, were present in 
three quarters (76 %) of fatal overdoses reported in 
the European Union. 
 In 2019, increases in the number of heroin/morphine 
deaths were observed in Czechia, Denmark, 
Germany, Italy, Luxembourg, Romania and Slovakia. 
Opioids other than heroin, including methadone, 
buprenorphine, fentanyl and its derivatives and 
tramadol, were associated with a substantial share 
of overdose deaths in some countries.
 The number of deaths involving fentanyl or its 
derivatives reported in the European Union 
declined in 2019. 
 Among the countries providing data, cocaine-related 
deaths increased in 2019. Cocaine, mostly in the 
presence of opioids, was involved in over half of the 
drug-induced deaths reported in Spain and over a 
quarter in France.
 Deaths linked to amphetamines were reported in 2019 
by Germany (124), Finland (48), Slovakia (13), Austria 
(13), Czechia (12) and Turkey (55). 
 Deaths linked to synthetic cannabinoids continued to 
fall in Turkey. However, the risks associated with these 
substances were underlined by an outbreak involving 
21 deaths reported in Hungary in 2020.
 Comparing the number of deaths over a longer time 
period, overdose deaths in the European Union have 
been increasing since 2012, overall and among 
teenagers and all age categories above 35, with 
the 74 % increase among the 50-plus age group 
particularly high. 
 In contrast with an overall ageing trend, 116 deaths 
were reported among teenagers aged 15-19 in 2019 
in the European Union, Norway and Turkey. Numbers 
have been stable or increased in several countries 
compared with 2012. These increases are based on 
relatively low numbers, but they should be considered 
with concern and the situation closely monitored.
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DRUG-INDUCED DEATHS
Data refer to the European Union,  except where indicated as ‘EU + 2’ (EU, Turkey and Norway). Where 2019 data were not available, 2018 or otherwise most recent 
data were used. Due to methodological differences and potential under-reporting in some countries, comparisons between countries may not be valid. 
Characteristics Age at death
Number of deaths
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Age distribution of drug-induced deaths reported in the European Union, Norway and Turkey in 2019, 
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National data for estimates of drug use prevalence including problem 
opioid use, substitution treatment, total number in treatment, treatment 
entry, injecting drug use, drug-induced deaths, drug-related infectious 
diseases, syringe distribution and seizures. The data are drawn from and 
are a subset of the EMCDDA Statistical Bulletin 2021, where notes and 
meta-data are available. The years to which data refer are indicated.
ANNEX
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Problem opioid use 
estimate




Opioids clients as % of treatment 
entrants
% opioids clients injecting 




















% (count) % (count) % (count) % (count) % (count) % (count) count













Bulgaria – – 80 (762) 46.1 (95) 90.2 (617) 66.2 (501) 55.3 (52) 66.2 (406) 3 072
Czechia 2019 1.5-1.6 11.3 (495) 7.6 (151) 14.9 (334) 66.3 (325) 62.4 (93) 68.7 (228) 5 000
Denmark 2016 4.0-9.6 11 (565) 6.3 (151) 15.6 (404) 15 (85) 2.6 (4) 19.8 (80) 6 600
Germany (1) 2018 2.2-2.6 16 (6 835) 8.5 (1972) – (–) 19.6 (915) 17.6 (246) – (–) 79 700
Estonia – – 93.4 (271) 87.4 (76) 95.5 (150) 69.3 (187) 72 (54) 80.7 (121) 1 054










































































Cyprus 2019 1.3-2.3 18.7 (182) 11.1 (62) 29.9 (117) 53 (96) 37.7 (23) 60.7 (71)  277
Latvia 2017 4.7-7.0 49.4 (399) 28.7 (123) 72.8 (276) 82.8 (323) 73.8 (90) 86.9 (233)  710
Lithuania 2016 2.7-6.5 80.5 (649) 48.7 (57) 87.8 (581) 77.9 (504) 73.7 (42) – (–) 1 033
Luxembourg 2018 3.5 46.2 (176) 25.4 (34) 59.4 (139) 48.7 (75) 53.1 (17) 47.9 (57) 1 099
Hungary 2010-11 0.4-0.5 3.5 (162) 1.6 (49) 8.9 (96) 43 (64) 22.4 (11) 54.3 (50)  629






















































Portugal 2018 3.0-7.0 34.2 (1 136) 17.8 (346) 57.6 (790) 11.4 (124) 7 (23) 13.4 (101) 16 867
Romania 2017 0.8-2.9 25.4 (1 087) 12.6 (390) 59 (697) 79.6 (855) 76.5 (293) 81.3 (562) 1 905
Slovenia 2019 2.3-2.4 79.6 (148) 60.8 (31) 86.7 (117) 37.8 (56) 12.9 (4) 44.4 (52) 3 301
Slovakia 2019 2.0-2.4 23.5 (774) 7.8 (100) 34 (648) 69.6 (530) 53.5 (53) 72.6 (464)  661
Finland 2017 6.9-8.6 46.1 (240) 35.8 (77) 53.3 (163) 74.1 (177) 74 (57) 74.1 (120) 3 329








– (–) – (–) 4 014
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– (–) – (–) – (–) 7 900
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Union











































High-risk opioid use estimates relate to the population aged 15-64 years.
Data on entrants into treatment are for 2019 or most recent year available: Bulgaria, Czechia, Denmark and Spain, 2018; Latvia, 2017; Estonia, 2016; Netherlands, 2015.
Data on clients in substitution treatment are for 2019 or most recent year available: Spain, France, Italy, Slovenia and Sweden, 2018; Denmark, 2017; Netherlands 
and Finland, 2015.
(1) Data for first-time entrants are for 2018.
(2) Data on the number of clients in substitution treatment are not complete.
(3)  Data for clients entering treatment refer to hospital-based care and specialised outpatient care facilities. Data shown are not fully representative of the national picture.
(4) The percentage of clients in treatment for opioid-related problems is a minimum value, not accounting for opioid clients registered as polydrug users.
(5) The high-risk opioid use estimate does not include Northern Ireland. Clients in substitution treatment relates to England and Wales.
Annex | National data tables 
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COCAINE
TABLE A2
 Country Year of survey
Prevalence estimates Entrants into treatment during the year
General population School popolation
Cocaine clients as % of treatment 
demands
% cocaine clients injecting 



















































Bulgaria 2016 0.9 0.5 3 4.2 (40) 10.7 (22) 2.3 (16) 0 (0) 0 (0) 0 (0)
Czechia 2019 1.7 0.3 2 0.9 (40) 1.2 (23) 0.8 (17) 2.6 (1) – (–) 6.2 (1)





















Estonia 2018 5.0 2.8 2 0.3 (1) 1.1 (1) – (–) – (–) – (–) – (–)
















































Croatia 2019 4.8 3.9 2 – (–) 6.3 (65) 1.7 (100) – (–) 6.2 (4) 6.1 (6)
























Latvia 2015 1.5 1.2 2 0.5 (4) 0.7 (3) 0.3 (1) 0 (0) 0 (0) 0 (0)
Lithuania 2016 0.7 0.3 2 1.9 (15) 6 (7) 0.6 (4) 21.4 (3) – (–) – (–)












Hungary 2019 1.7 0.6 3 4.1 (186) 4.5 (141) 3.3 (36) 0.5 (1) 0 (0) 2.8 (1)




































Poland 2018 0.7 0.5 2 3.1 (202) 2.8 (86) 3.5 (112) 0.5 (1) 0 (0) 0.9 (1)












Romania 2019 1.6 0.7 2 2.5 (107) 3 (94) 1.1 (13) 0 (0) 0 (0) 0 (0)
Slovenia 2018 2.7 1.8 3 4.8 (9) 3.9 (2) 5.2 (7) 22.2 (2) 0 (0) 28.6 (2)
Slovakia 2019 0.9 0.2 1 1.3 (44) 2.1 (27) 0.8 (15) 2.5 (1) – (–) 7.7 (1)
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 Country Year of survey
Prevalence estimates Entrants into treatment during the year
General population School popolation
Cocaine clients as % of treatment 
demands
% cocaine clients injecting 







































Finland 2018 3.2 1.5 1 0.4 (2) 0.9 (2) 0 (0) 0 (0) 0 (0) 0 (0)
Sweden (2) 2017 – 2.5 2 1.8 (788) 3.4 (470) 0.8 (223) 25 (1) – (–) – (–)
Turkey 2017 0.2 0.1 – 2.6 (291) 2.6 (109) 2.4 (163) 0 (0) 0 (0) 0 (0)
Norway 2019 5.2 2.8 2 2.9 (178) 3.8 (102) 2.2 (76) – (–) – (–) – (–)
European 
Union








































Prevalence estimates for the general population: United Kingdom estimates refer to England and Wales only. Age ranges are 18-64 and 18-34 for France, Germany, 
Greece and Hungary; 16-64 and 16-34 for Denmark, Estonia, United Kingdom and Norway; 18-65 for Malta; 17-34 for Sweden.
Prevalence estimates for the school population are extracted from the 2019 ESPAD survey, except for Belgium (2019; Flanders only), Luxembourg (2014) 
and United Kingdom (2018; England only, age 15 years). Germany ESPAD 2019 data refer to Bavaria only.
Data on entrants into treatment are for 2019 or most recent year available: Bulgaria, Czechia, Denmark and Spain, 2018; Latvia, 2017; Estonia, 2016; Netherlands, 2015.
(1) Data for first-time entrants are for 2018.
(2)  Data for clients entering treatment refer to hospital-based care and specialised outpatient care facilities. Data shown are not fully representative 
of the national picture.
Annex | National data tables 
48
European Drug Report 2021: Trends and Developments
AMPHETAMINES
TABLE A3
 Country Year of survey
Prevalence estimates Entrants into treatment during the year
General population School popolation
Amphetamines clients as % of 
treatment demands
% amphetamines clients injecting 



















































Bulgaria 2016 1.5 1.8 3 10 (95) 24.3 (50) 5.3 (36) 6.5 (6) 2 (1) 2.9 (1)












Denmark 2017 7.0 1.4 1 6.1 (312) 5 (121) 7.1 (183) 3 (9) 2.5 (3) 3.5 (6)









Estonia 2018 6.1 2.1 3 3.8 (11) 6.9 (6) 2.5 (4) 50 (5) 66.7 (4) 33.3 (1)
























Spain 2020 4.3 1.1 1 1.6 (755) 1.7 (425) 1.4 (305) 1.2 (9) 1.9 (8) 0.3 (1)












Croatia 2019 4.6 3.5 2 – (–) 5.6 (58) 1.1 (67) – (–) 1.8 (1) 0 (0)
Italy 2017 2.4 0.3 1 0.2 (89) 0.3 (55) 0.2 (34) 2.6 (2) 2.2 (1) 3.1 (1)
































– (–) – (–)
Luxembourg 2019 1.3 0.3 1 0.5 (2) – (–) 0.9 (2) – (–) – (–) – (–)












Malta 2013 0.3 – 1 0.3 (5) 0.6 (2) 0.2 (3) 20 (1) 50 (1)
Netherlands 2019 5.5 4.1 1 7.4 (817) 7.5 (487) 7.4 (330) 1.3 (4) 1 (2) 1.9 (2)
Austria 2015 2.2 0.9 2 5.4 (233) 5.9 (107) 5 (126) 1.9 (4) 2.1 (2) 1.7 (2)












Portugal 2016 0.4 0.0 2 0.1 (4) 0.2 (3) 0.1 (1) 0 (0) 0 (0) 0 (0)
Romania 2019 0.2 0.1 1 1.3 (54) 1.5 (47) 0.6 (7) 0 (0) 0 (0) 0 (0)
Slovenia 2018 2.3 1.1 1 1.1 (2) 2 (1) 0.7 (1) 0 (0) 0 (0) 0 (0)

























Annex | National data tables 
 Country Year of survey
Prevalence estimates Entrants into treatment during the year
General population School popolation
Amphetamines clients as % of 
treatment demands
% amphetamines clients injecting 











































5 (1 351) 51.9 
(70)
– (–) – (–)


















– (–) – (–) – (–)
European 
Union








































Prevalence estimates for the general population: United Kingdom estimates refer to England and Wales only. Age ranges are 18-64 and 18-34 for France, Germany 
and Hungary; 16-64 and 16-34 for Denmark, Estonia, United Kingdom and Norway; 18-65 for Malta; 17-34 for Sweden.
Prevalence estimates for the school population are extracted from the 2019 ESPAD survey, except for Belgium (2019; Flanders only), Luxembourg (2014) and 
United Kingdom (2018; England only, age 15 years). Germany ESPAD 2019 data refer to Bavaria only.
Data on entrants into treatment are for 2019 or most recent year available: Bulgaria, Czechia, Denmark and Spain, 2018; Latvia, 2017; Estonia, 2016; Netherlands, 2015.
Data on entrants into treatment for Sweden and Norway are for ‘stimulants other than cocaine’.
(1) Data for first-time entrants are for 2018.
(2)  Data for clients entering treatment refer to hospital-based care and specialised outpatient care facilities. Data shown are not fully representative 
of the national picture.
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TABLE A4
 Country Year of survey
Prevalence estimates Entrants into treatment during the year


















% (count) % (count) % (count)
Belgium 2018 – 2.5 2 0.4 (46) 0.7 (31) 0.1 (10)
Bulgaria 2016 2.1 3.1 3 0.7 (7) 3.4 (7) 0 (0)
Czechia 2019 5.6 3.2 4 0.3 (14) 0.4 (7) 0.2 (5)
Denmark 2017 3.2 1.5 2 – (–) – (–) – (–)
Germany (1) 2018 3.9 2.8 2 0.8 (328) 0.8 (176) – (–)
Estonia 2018 5.4 2.5 5 0.3 (1) – (–) 0.6 (1)
Ireland 2015 9.2 4.4 3 0.4 (45) 0.9 (37) 0.1 (8)
Greece 2015 0.6 0.4 1 0.2 (6) 0.3 (5) 0 (1)
Spain 2020 5.0 1.6 1 0.2 (72) 0.2 (57) 0.1 (14)
France 2017 3.9 1.3 2 0.4 (192) 0.5 (66) 0.3 (52)
Croatia 2019 4.2 2.6 2 – (–) 0.7 (7) 0.2 (13)
Italy 2017 2.7 0.8 1 0.2 (59) 0.1 (24) 0.2 (35)
Cyprus 2019 1.2 0.4 3 0.1 (1) – (–) 0.3 (1)
Latvia 2015 2.4 0.8 5 0.4 (3) 0.2 (1) 0.5 (2)
Lithuania 2016 1.7 1.0 3 0.1 (1) – (–) – (–)
Luxembourg 2019 2.0 0.9 1 – (–) – (–) – (–)
Hungary 2019 2.5 1.1 3 2.4 (109) 2.5 (78) 1.9 (21)
Malta 2013 0.7 – 1 0.9 (18) 1.2 (4) 0.9 (14)
Netherlands 2019 10.8 8.5 3 0.7 (80) 1 (67) 0.3 (13)
Austria 2015 2.9 1.1 3 0.8 (36) 1.1 (20) 0.6 (16)
Poland 2018 1.0 0.5 3 0.4 (28) 0.5 (16) 0.3 (11)
Portugal 2016 0.7 0.2 3 0.5 (15) 0.8 (15)
Romania 2019 1.0 0.8 1 1.8 (77) 2.3 (72) 0.4 (5)
Slovenia 2018 2.9 1.3 3 1.6 (3) 3.9 (2) 0.7 (1)
Slovakia 2019 3.1 1.0 3 0.3 (10) 0.4 (5) 0.3 (5)
Finland 2018 5.0 2.6 1 0.6 (3) 0.5 (1) 0.7 (2)
Sweden 2017 – 2.0 2 – (–) – (–) – (–)
Turkey 2017 0.4 0.2 – 2.2 (239) 3.1 (133) 1.5 (103)
Norway 2019 3.3 1.1 2 – (–) – (–) – (–)
European Union – 3.6 1.9 – 0.4 (1 154) 0.5 (698) 0.2 (230)
EU, Turkey and Norway – – – – 0.4 (1 393) 0.6 (831) 0.2 (333)
United Kingdom 2018 9.1 3.1 4 0.4 (450) 0.9 (324) 0.2 (126)
Prevalence estimates for the general population: United Kingdom estimates refer to England and Wales only. Age ranges are 18-64 and 18-34 for France, Germany, 
Greece and Hungary; 16-64 and 16-34 for Denmark, Estonia, United Kingdom and Norway; 18-65 for Malta; 17-34 for Sweden.
Prevalence estimates for the school population are extracted from the 2019 ESPAD survey, except for Belgium (2019; Flanders only), Luxembourg (2014) and 
United Kingdom (2018; England only, age 15 years). Germany ESPAD 2019 data refer to Bavaria only.
Data on entrants into treatment are for 2019 or most recent year available: Bulgaria, Czechia, Denmark and Spain, 2018; Latvia, 2017; Estonia, 2016; Netherlands, 2015.
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 Country Year of survey
Prevalence estimates Entrants into treatment during the year


















% (count) % (count) % (count)
Belgium 2018 22.6 13.6 17 32.5 (3 824) 47.9 (2 017) 23.4 (1 602)
Bulgaria 2016 8.3 10.3 17 4.2 (40) 12.1 (25) 2 (14)
Czechia 2019 25.9 17.8 28 12.8 (563) 16.3 (326) 9.8 (219)
Denmark 2017 38.4 15.4 17 60.6 (3 109) 64.1 (1 540) 57.2 (1 482)
Germany (1) 2018 28.2 16.9 22 58.5 (24 902) 68.3 (15 895) – (–)
Estonia 2018 24.5 16.6 20 1 (3) 2.3 (2) 0.6 (1)
Ireland 2015 27.9 13.8 19 23.4 (2 406) 37.9 (1 504) 12.5 (691)
Greece 2015 11.0 4.5 8 28.2 (1 106) 46.5 (768) 14.8 (334)
Spain 2020 37.5 19.1 23 28.1 (13 459) 38.5 (9 485) 15.8 (3 386)
France 2017 44.8 21.8 23 59 (27 400) 73.3 (8 934) 43.6 (7 872)
Croatia 2019 22.9 20.3 21 – (–) 57.1 (586) 7.7 (453)
Italy 2017 32.7 20.9 27 22.1 (8 451) 30.3 (4 880) 16.1 (3 571)
Cyprus 2019 14.1 8.1 8 50.3 (490) 63.6 (354) 32 (125)
Latvia 2015 9.8 10.0 26 24 (194) 36 (154) 10.6 (40)
Lithuania 2016 10.8 6.0 18 6.3 (51) 23.1 (27) 3.3 (22)
Luxembourg 2019 23.3 12.0 19 33.6 (128) 62.7 (84) 17.1 (40)
Hungary 2019 6.1 3.4 13 64.2 (2 942) 69.3 (2 167) 49.4 (533)
Malta 2013 4.3 – 12 14.3 (278) 29.1 (101) 11.1 (177)
Netherlands 2019 27.7 15.5 22 47.3 (5 202) 55.5 (3 625) 35.4 (1 577)
Austria 2015 23.6 14.1 21 32.5 (1 403) 47.6 (856) 21.7 (547)
Poland 2018 12.1 7.8 21 32.8 (2 128) 40.1 (1 243) 26.2 (847)
Portugal 2016 11.0 8.0 13 39.6 (1 314) 52.3 (1 018) 21.6 (296)
Romania 2019 6.1 6.0 9 54.5 (2 336) 66 (2047) 24.5 (289)
Slovenia 2018 20.7 12.3 23 9.7 (18) 27.5 (14) 3 (4)
Slovakia 2019 17.0 7.7 24 21.2 (699) 31.8 (409) 14.1 (269)
Finland 2018 25.6 15.5 11 15.9 (83) 25.6 (55) 9.2 (28)
Sweden (2) 2018 16.7 7.9 8 10.7 (4 564) 14.2 (1 994) 7.2 (1 938)
Turkey 2017 2.7 1.8 – 11 (1 220) 15.3 (654) 7.8 (522)
Norway 2019 23.2 10.5 9 30.2 (1 831) 38.7 (1 026) 23.6 (805)
European Union – 27.2 15.4 – 36 (107 093) 46.8 (60 110) 19.6 (26 357)
EU, Turkey and Norway – – – – 35 (110 144) 45.6 (61 790) 19.2 (27 684)
United Kingdom 2018 29.0 13.4 23 23.5 (26 816) 43 (15 181) 14.7 (11 537)
Prevalence estimates for the general population: United Kingdom estimates refer to England and Wales only. Age ranges are 18-64 and 18-34 for France, Germany, 
Greece and Hungary; 16-64 and 16-34 for Denmark, Estonia, Sweden, United Kingdom and Norway; 18-65 for Malta.
Prevalence estimates for the school population are extracted from the 2019 ESPAD survey, except for Belgium (2019; Flanders only), Luxembourg (2018) and 
United Kingdom (2018; England only, age 15 years). Germany ESPAD 2019 data refer to Bavaria only. Due to possible overstating, Luxembourg cannabis lifetime 
prevalence may be slightly overestimated.
Data on entrants into treatment are for 2019 or most recent year available: Bulgaria, Czechia, Denmark and Spain, 2018; Latvia, 2017; Estonia, 2016; Netherlands, 2015.
(1) Data for first-time entrants are for 2018.
(2)  Data for clients entering treatment refer to hospital-based care and specialised outpatient care facilities. Data shown are not fully representative of the national picture.
52





























Belgium 2014 61 8 (60) 1.1 (12) 2019 0.5-1.0 1 262 773
Bulgaria 2019 11 2 (11) 5.3 (37) – –  124 746
Czechia 2019 42 5 (37) 0.6 (6) 2019 5.8-6.1 7 459 123
Denmark 2018 173 39 (146) 0.7 (4) – – –
Germany 2019 1398 – (–) 1.9 (159) – – 4 197 853
Estonia 2019 27 30 (25) 15.1 (20) 2015 9.0-11.3 1 629 477
Ireland 2017 235 71 (227) 2 (10) – –  532 761
Greece (1) 2017 57 8 (52) 6.7 (72) 2019 0.4-0.7  464 745
Spain 2018 450 15 (450) 1.4 (68) 2018 0.2-0.5 1 812 069
France 2016 465 9 (391) 1 (65) 2019 3.1-3.3 12 840 577
Croatia 2019 97 37 (97) 0.2 (1) 2015 1.8-2.9  341 900
Italy 2019 373 10 (369) 2.4 (147) – – –
Cyprus 2019 5 8 (5) 3.4 (3) 2019 0.8-1.5   878
Latvia 2019 12 10 (12) 22.9 (44) 2016 5.3-6.8  968 059
Lithuania 2019 52 29 (52) 17.2 (48) 2016 4.4-4.9  241 361
Luxembourg 2019 8 19 (8) 0 (0) 2018 1.9  430 078
Hungary 2019 43 7 (43) 0.1 (1) 2015 1.0  44 602
Malta 2018 3 9 (3) 0 (0) – –  223 936
Netherlands 2019 252 20 (224) 0.1 (2) 2015 0.07-0.09 –
Austria 2019 196 33 (193) 2.1 (19) – – 6 164 781
Poland 2018 199 6 (153) 0.5 (19) – –  181 913
Portugal 2018 55 8 (51) 1.6 (16) 2015 1.0-4.5 1 414 228
Romania (2) 2019 45 3 (44) 3.3 (65) – – 1 181 768
Slovenia 2019 74 51 (69) 1 (2) – –  502 369
Slovakia 2019 34 8 (29) 0 (0) – –  441 954
Finland 2019 234 65 (224) 1.4 (8) 2012 4.1-6.7 7 055 191
Sweden 2019 540 77 (490) 2.1 (21) – –  999 523
Turkey 2019 342 6 (333) 0.1 (10) – – –
Norway 2018 286 77 (267) 1.5 (8) 2018 2.0-2.8 3 081 586
European Union –  5 141 15 (3 465) 1.9 (849) – – –
EU, Turkey and Norway –  5 769 14 (4 065) 1.6 (867) – – –
United Kingdom (3) 2017  3 284 76 (3 126) 1.6 (108) – – –
Overdose data must be interpreted with caution. Methodological differences should be considered when comparing between countries. In some cases, the age 
band is not specified, and these cases were not included in the calculations of mortality rate referring to the population aged 15-64 years: Germany (1 398),  
Greece (5), Romania (1) and Turkey (7). 
HIV diagnoses related to injecting drug use are from 2019, except for Belgium, which are from 2018.
Injecting drug use estimates refer to the population aged 15 to 64 years.
Syringes distributed through specialised programmes refer to 2019, except for Germany and Spain (2018) and France (2017). United Kingdom syringe data:  
England, no data; Wales, 2 564 798 in 2019; Scotland, 4 401 387 in 2017; Northern Ireland, 387 825 in 2018.
(1)  Drug-induced deaths in Greece in 2017 include 52 confirmed cases and 5 still under investigation.
(2)  Drug-induced deaths data with sub-national coverage: 4 counties out of 42 recorded drug-induced cases (Bucharest, Teleorman, Cluj and Hunedoara).

























kg count kg count kg count tablets (kg) count
Belgium  1 929  1 695  65 248  5 869  1 052  3 098  409 007   250  2 748
Bulgaria   787   32   318   25   97   79  2 184   107   39
Czechia   9   105   187   290   28  1 800  74 832   37   407
Denmark   46   513   190  5 477   217  2 480  35 568   66  1 096
Germany   298  2 991  8 166  3 520  1 669  13 894  693 668 –  3 355
Estonia <0.1   4   17   149   115   347 –   34   199
Ireland –  1 305 –  2 266 –   277 – –   978
Greece   403  2 355   953   812  9 629   303  169 269   2   107
Spain   234  7 421  37 868  48 048  2 043  5 045  270 836   340  5 721
France  1 073  4 103  15 761  12 578   725 – 1 699 848 –  1 048
Croatia   12   116   16   575   41   958 –   16   822
Italy   615  2 414  8 245  8 658   50   349  19 338   37   328
Cyprus <0.1   13   49   159   1   129  2 400 0   19
Latvia <0.1   16  2 202   184   108   554  96 003   4   507
Lithuania   2   50   16   133   28   360 –   283   189
Luxembourg   6   138   2   235   0.1   11  46 059 – 32
Hungary   77   37   30   365   46  1 084  66 829   2   803
Malta   1   12   747   92 – –   149   <0.1   46
Netherlands (1)  1 326 –  43 836 –  1 025 – – 599 –
Austria   95  1 267   87  2 089   152  2 312  77 922   9  1 501
Poland   21   1  2 248   12  2 214   85  260 112   323   16
Portugal   15   201  10 567   578   3   32  15 133   2   218
Romania   138   281  16 157   534   7   257  47 283   4   991
Slovenia   759   193   4   267   28   258  9 763   0.2   83
Slovakia   2   52   0.3   51   9   781  1 329   0.3   100
Finland   8   88   223   441   190  2 194  265 511   29   665
Sweden   64   861   121  4 449  1 000  7 719  347 038   59  2 636
Turkey  20 165  16 265  1 634  3 018  3 831  24 970 8 695 605 –  8 530
Norway   88   683   136  1 529   467  5 183  120 474   44  1 167
European Union  7 919  26 264  213 259 97 856 20 480  44 406 4 610 081  2 204  24 654
EU, Turkey and Norway  28 172  43 212  215 029  102 403  24 778  74 559 13 426 160  2 248  34 351
United Kingdom   617  10 868  3 469  19 451  1 668  3 682  713 896   1  3 630
All data are for 2019 or most recent year. Amphetamines includes amphetamine and methamphetamine.
(1)  Data on number and quantity of seizures do not include all relevant law enforcement units and should be considered partial, minimum figures. Cocaine and heroin 
seizures represent the majority of large seizures.
Annex | National data tables 
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kg count kg count plants (kg) count
Belgium   108  6 889  17 290  28 801  422 261 –  1 006
Bulgaria 0.6   13 2 939   73 25 696  46 713   124
Czechia   2   138   546 5 417 26 925 – 476
Denmark 2 399 19 312   492 3 503 12 575 124   443
Germany 1 295 5 679 7 731 31 378 101 598 – 2 220
Estonia   2   46   97   807 – 75   31
Ireland – 422 –  3 072 – –   197
Greece 6 587   333 12 515 9 597 56 963 – 584
Spain 349 489 187 328 39 861 143 922 1538 995 – 3 074
France 74 340 76 227 29 952 30 175 180 509 – 462
Croatia   148   441 2 231 6 622 3 044 – 118
Italy 20 986 9 225 23 632 9 988 223 541 – 1 172
Cyprus   60   30   227   818   158 – 22
Latvia   372   92   63 1 021 – 100   52
Lithuania 1 775   34   220   986 – – –
Luxembourg   273   545   98   651   22 –   3
Hungary   2   185   715 3 111 7 128 – 158
Malta   118   28   389   144   2 –   1
Netherlands (1)  1 552 – – – 556 802 – –
Austria   147 1 081 1 216 15 136 26 568 – 516
Poland   436   32 3 495   281 93 090 –   7
Portugal 3 234 1 709   492   369 12 077 – 131
Romania   21   303 1 207 3 625 – 517   120
Slovenia   9   113   704  3 854  8 810 0.34   230
Slovakia 0.5   27   131 1 075 1 611 – 41
Finland   215   303   397 1 128 15 900 –  1 668
Sweden 1 832 15 484 1 009 7 718 – – –
Turkey 27 889 6 162 62 685 63 531 42 276 694 –  2 986
Norway 2 244 10 202   458 2 724 – – –
European Union  465 404  326 019 147 650  313 272 3 314 275  47 529  12 856
EU, Turkey and 
Norway
 495 537  342 383  210 793  379 527 45 590 969  47 529  15 842
United Kingdom  8 470  11 876  29 533  101 744  372 207 –  8 382
All data are for 2019 or most recent year.
(1) Data on number and quantity of seizures do not include all relevant law enforcement units and should be considered partial, minimum figures.
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The Trends and Developments report presents a top-level 
overview of the drug phenomenon in Europe focused 
on illicit drug use, related health harms and drug supply. 




In addition to the yearly European Drug Report, the EMCDDA 
publishes Health and Social Responses to Drug Use: A 
European Guide and, together with Europol, the European Drug 
Markets Report, alongside a wide range of detailed reports 
across the full spectrum of drugs issues. 
emcdda.europa.eu/publications
Best Practice
The Best Practice Portal provides practical and reliable 
information on what works (and what doesn’t) in the 
areas of prevention, treatment, harm reduction and 
social reintegration. It will help you identify tried and 
tested interventions quickly, allocate resources to what’s 




The annual Statistical Bulletin contains the most recent 
available data on the drug situation in Europe provided 
by the Member States. These datasets underpin the 
analysis presented in the European Drug Report. All data 




Hub pages and the A-Z index help you find EMCDDA 
content by topic. 
emcdda.europa.eu/topics
Document Library
The EMCDDA Document Library gives you access to 
documents related to the agency or collected by it in its 
work. There you can access publications by international and 
national organisations, scientific articles by EMCDDA staff, 
material published by other institutions of the European 




For in-depth information on illicit drugs consult 
EMCDDA publications and online resources.

 Getting in touch with the EU
In person
All over the European Union there are hundreds of Europe Direct 
information centres. You can fi nd the address of the centre nearest you at: 
https://europa.eu/european-union/contact_en
On the phone or by email
Europe Direct is a service that answers your questions about the 
European Union. You can contact this service:
–  by freephone: 00 800 6 7 8 9 10 11 (certain operators may charge 
for these calls),
– at the following standard number: +32 22999696 or
– by email via: https://europa.eu/european-union/contact_en
Finding information about the EU
Online
Information about the European Union in all the offi  cial languages of the 
EU is available on the Europa website at: https://europa.eu/european-
union/index_en
EU publications
You can download or order free and priced EU publications at: 
https://publications.europa.eu/en/publications. Multiple copies of free 
publications may be obtained by contacting Europe Direct or your local 
information centre (see https://europa.eu/european-union/contact_en).
EU law and related documents
For access to legal information from the EU, including all EU law since 
1952 in all the offi  cial language versions, go to EUR-Lex at: 
http://eur-lex.europa.eu
Open data from the EU
Th e EU Open Data Portal (http://data.europa.eu/euodp/en) provides 
access to datasets from the EU. Data can be downloaded and reused 
for free, both for commercial and non-commercial purposes.
About this report
Th e Trends and Developments report presents the 
EMCDDA’s latest analysis of the drug situation in 
Europe. Focusing on illicit drug use, related harms and 
drug supply, the report contains a comprehensive set 
of national data across these themes and key harm 
reduction interventions.
About the EMCDDA
Th e European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) is the central source and 
confi rmed authority on drug-related issues in Europe. 
For 25 years, it has been collecting, analysing and 
disseminating scientifi cally sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
Th e EMCDDA’s publications are a prime source of 
information for a wide range of audiences including 
policymakers and their advisors; professionals and 
researchers working in the drugs fi eld; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
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